聯邦醫療保險推出減肥藥物新方案
Medicare launches new program for weight-loss medication
Updated at: June 26, 2026 at 08:15 AM
自2026年7月1日起，聯邦醫療保險（Medicare）將啟動「GLP-1橋接計畫」（GLP-1 Bridge Program），這是一項為期18個月的重大試點專案，旨在改善民眾取得減重藥物的管道。
Starting July 1, 2026, Medicare is launching the GLP-1 Bridge Program, a significant 18-month pilot project aimed at improving access to weight-loss medications.
多年來，聯邦法律禁止Medicare給付僅用於體重管理的藥物。
For years, federal law prohibited Medicare from covering drugs solely for weight management.
這項新的示範計畫透過提供特定GLP-1受體致效劑藥物（包含Wegovy、Zepbound與Foundayo）的給付來改變現狀。
This new demonstration project changes that by providing coverage for specific GLP-1 receptor agonist medications, including Wegovy, Zepbound, and Foundayo.
若要參加，受益人必須擁有Medicare D部分（Part D）保險，並符合基於身體質量指數（BMI）與既有健康狀況的特定臨床標準。
To participate, beneficiaries must have Medicare Part D coverage and meet specific clinical criteria based on Body Mass Index (BMI) and pre-existing health conditions.
該計畫旨在使這些高昂的治療變得更平價，參加者每月需支付50美元的定額共付額（Copayment），即可獲得30天的藥量。
The program is designed to make these high-cost treatments more affordable, with participants paying a flat $50 monthly copayment for a 30-day supply.
此共付額與D部分標準費用無關。
This copayment is independent of standard Part D costs.
藉由測試這條新的給付途徑，聯邦醫療保險與醫療補助服務中心（CMS）希望收集關於臨床結果與成本效益的關鍵數據。
By testing this new coverage pathway, the Centers for Medicare & Medicaid Services (CMS) hopes to gather crucial data on clinical outcomes and cost-effectiveness.
這為長者提供了一個關鍵機會，能獲得以往難以取得且具有實證基礎的照護。
It offers a vital opportunity for seniors to access evidence-based care that was previously out of reach.
